Pilot Decentralized Trial
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: ALTO-100 PO Tablet
- Registration Number
- NCT05419869
- Lead Sponsor
- Alto Neuroscience
- Brief Summary
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-100.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
- Have a diagnosis of moderate to severe major depressive disorder
- Either currently taking a SSRI, SNRI, mirtazapine, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks, or are not taking an antidepressant medication
- Willing to comply with all study assessments and procedures
- Must not be pregnant or breastfeeding at time of enrollment or throughout study
- Must have access with privacy to a computer with a keyboard and internet
- Evidence of acute or unstable cardiovascular, respiratory, hepatic, or other major disease
- Active suicidal ideation
- Severe impediment to vision, hearing, and/or hand movement
- Diagnosed bipolar disorder or psychotic disorder
- Has a history of hypersensitivity or allergic reaction to ALTO-100 or any of its components/excipients
- Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ALTO-100 ALTO-100 PO Tablet ALTO-100 tablet PO ; twice daily dosing 8 weeks
- Primary Outcome Measures
Name Time Method To understand the relationship between baseline biology and score change in the Montgomery-Asberg Depression Rating Scale (MADRS) with ALTO-100 from start of dosing to end of treatment Measured at Day 1, Day 14, Day 28, Day 42, Day 56 The Montgomery-Åsberg Depression Rating Scale (MADRS) measures the severity of depression where smaller scores indicate less depression and higher scores suggest more severe depression. Possible scores for this 10 item version range from 0 to 60. The score change from the start of dosing (Day 1) to the end of treatment (Day 56) is the primary outcome.
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100 From the signing of the ICF until the follow-up visit (up to 13 weeks) An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100 From the signing of the ICF until the end-of-treatment visit (up to 13 weeks) Blood samples for serum chemistry and hematology will be collected for clinical laboratory testing.
To understand the relationship between baseline biology and score change in the Clinical Global Impression scale - Severity (CGI-S) with ALTO-100 from Screening to end of treatment Measured at Screening, Day 1, Day 14, Day 28, Day 42, Day 56 The Clinical Global Impression scale - Severity (CGI-S) measures the severity of psychopathology in general where smaller scores indicate less illness and higher scores suggest more severe illness. Possible scores for this scale range from 1 to 7. The score change from Screening (Day \[-21\]) to the end of treatment (Day 56) is the primary outcome.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Site 156
🇺🇸Jackson, Mississippi, United States
Site 160
🇺🇸Coral Gables, Florida, United States